Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Lung
14:08

Dana-Farber Cancer Institute

Risk of Hepatotoxicity From Sequential IO Followed by KRASG12C Targeted Therapy in NSCLC

FEATURING Biagio Ricciuti
  • 219 views
  • May 22, 2024
  • 1
29:32

Dana-Farber Cancer Institute

Updates in KRAS G12C Mutant NSCLC: Demographics, Clinical Features, Genomics, and Treatment

FEATURING Biagio Ricciuti
  • 232 views
  • January 8, 2024
  • 1
02:35

ecancer

ESMO 2023 Insights: "Phase 2 KRYSTAL-7 Trial - Adagrasib+Pembro Combo for KRASG12C+, Treatment-Naïve, Advanced NSCLC"

FEATURING Pasi Janne
  • 95 views
  • October 25, 2023
05:48

Insights from 2023 WCLC

WCLC 2023 Insights: "Association of TTF-1 Expression With Outcomes to IO & KRAS G12C Inhibition in Lung Adenocarcinoma"

FEATURING Alessandro Di Federico
  • 85 views
  • October 17, 2023
  • 1
09:08

Insights from 2023 WCLC

WCLC 2023 Insights: "Mechanisms of Resistance to KRAS G12C Inhibitors in NSCLC"

FEATURING Biagio Ricciuti
  • 95 views
  • October 9, 2023
  • 1
09:57

Insights from 2023 WCLC

WCLC 2023 Insights: "3-Year Outcomes & Correlative Analyses in Patients With NSCLC and a Very High PD-L1 Tumor Proportion Score ≥ 90% Treated With 1L Cemiplimab & Pembro"

FEATURING Biagio Ricciuti
  • 97 views
  • October 9, 2023
  • 1
15:30

Dana-Farber Cancer Institute

Small Cell Lung Cancer: A Brief Review of the Treatment Landscape

FEATURING Jacob Sands
  • 610 views
  • November 8, 2021
  • 3